INTRODUCTION

Poly (Adenosine Diphosphate [ADP]) Ribose Polymerase Function Inhibition and Synthetic Lethality in Homologous Recombination-Deficient Cells
DNA is constantly under repair due to the damaging byproducts of cellular metabolism, de novo disruption of chemical bonds, and exposure to environmental agents. 1 The most common DNA aberration is discontinuity in 1 strand, also known as a single-strand break (SSB), which is predominantly repaired via base excision repair mechanisms, but also by nucleotide excision repair and, to a much lesser extent, DNA mismatch repair. SSB repair requires the orchestration of several proteins, including polyadenosine diphosphate (ADP) ribose polymerase 1 (PARP1) and 2 (PARP2). PARP1 and PARP2 catalyze the addition of poly (ADP)-ribose (also known as PARylation) from nicotinamide adenine dinucleotide molecules to client proteins in malignant and nonmalignant cells and to PARP1/2 themselves (Fig. 1) . 2 There are 17 members of the PARP family, of which PARP1 was the first to be described. 3 PARP1 is responsible for the majority of PARylation in malignant and nonmalignant cells, which is essential for the efficiency of cellular functions including DNA repair and chromatin regulation. 4, 5 PARP1 acts as a DNA damage sensor and binds to the site of SSBs, increasing its enzymatic activity by as much as 500-fold (Fig. 1A) . 6 PARP1 binding results in the recruitment and PARylation of several different DNA repair proteins, including DNA polymerase beta and XRCC1 to repair the SSB (Fig. 1) . 7 The recruitment of these proteins causes destabilization and disassociation of the PARP-DNA interaction, which is necessary for DNA repair to proceed. 8 If the repair of SSBs is deficient or disabled, SSBs can be converted to double-strand breaks (DSBs) due to collapse or blockage of DNA replication forks during the S-phase of the cell cycle. 9 In this situation, the mechanisms of DSB repair will be activated and attempt to repair the lesion. 10 Cells have developed sophisticated mechanisms with which to repair DSBs to maintain genetic fidelity because unrepaired or misrepaired DSBs can result in senescence, genetic instability, apoptosis, and transformation. 10 For example, PARP1 knockout mice are deficient in the repair of SSBs but accomplish DNA repair through redundantly using, preferentially, one arm of the DSB repair pathway known as homologous recombination (HR). Due to this failsafe, PARP1 knockout mice are viable with no visible phenotypes of infertility or an increased risk of malignancy. 11 The majority of DSB repair is accomplished by 2 mechanisms: HR and nonhomologous end joining (NHEJ) (Fig. 1B) . HR is slower and more accurate because it uses the sister chromatid as a template during the S-phase/G2 phases of the cell cycle. 12 NHEJ is faster but more prone to error because damaged ends are directly ligated. 12 BRCA Loss, DNA Repair, and Synthetic Lethality BRCA1 and BRCA2 are large nuclear proteins that play an integral role in the HR pathway. 13 Loss of function of BRCA1 and/or BRCA2 disrupts HR and DSB repair, resulting in the use of more error-prone pathways (NHEJ or the single-strand annealing subpathway of HR) (Fig. 1B) .
14 Women who inherit a BRCA1/2 mutation have an estimated lifetime risk of 40% to 80% of developing breast cancer and an 11% to 40% risk of developing ovarian cancer. 15 In patients with germline BRCA1/2 carrier mutations, tumors typically have a somatic loss of heterozygosity with de novo DNA structural aberration of the remaining functional BRCA allele. 16 DSB repair in BRCA-deficient tumors is largely dependent on NHEJ for the repair of DSBs (Fig. 1B) . 14 The polymerase POLQ also recently has been shown to be redundant to HR and facilitates an essential bypass mechanism for DSBs in HRdeficient tumors. 17, 18 Although cells deficient in either PARP or BRCA alone are viable, the loss of both results in a lethal phenotype. This concept, known as "synthetic lethality," to our knowledge first was described by Dobzhansky in 1946 and in 1997 by Hartwell et al, who suggested its application to cancer therapeutics. 19, 20 In 2005, 2 groups demonstrated that treatment of BRCA1-deficient or BRAC2-deficient normal and tumor cells with PARP inhibitors (PARPis) resulted in synergistic cell death associated with unrepaired DSBs. 21, 22 The creation of synthetic lethality by combining PARPis with BRCA loss intrinsic to the tumor proved that a genetic vulnerability could be exploited for selective treatment to minimize off-target toxicity. The relatively low frequency of germline BRCA1/2 mutations associated with prostate cancer (PCa) and bladder urothelial cell carcinoma (UC) initially appeared to limit the clinical applicability of PARPi to genitourinary (GU) tumors. 23, 24 However, it was hypothesized that this synthetic lethal approach with PARPis was not solely dependent on inherited BRCA1 or BRAC2 loss alone but could possibly extend to other germline or somatic deficiencies in the HR pathway.
PARP Inhibitors: Mechanism of Action
Small molecule PARPis have existed for nearly 30 years and have progressed through several generations of chemical modification. Modifications have improved selectivity and potency, but all PARPis have a nicotinamide pharmacophore that results in competitive inhibition by binding/ blocking the catalytic domain of PARP1 and PARP2. 25 PARP2 is far less abundant and is responsible for 5%-10% of total PARylation in response to DNA damage. 26 All currently studied PARPis bind to both PARP1 and PARP2 (Table 1) . The original primary mechanism of action for the cytotoxicity of PARPis was attributed to the generation of SSBs and a resultant overwhelming number of DSBs via catalytic inhibition of PARP1. 22 A second and possibly equally important mechanism of PARPi action was shown by Murai et al, 27 in which PARPis trap PARP1/2 at the sites of DNA damage, known as "PARP trapping." Although the interaction between PARP1/2 and DNA is normally reversible, PARPis may induce stabilization of the interaction. 27 The irreversibly bound PARP-DNA complex prevents DNA repair, transcription, and replication, and ultimately is cytotoxic. 28 Evidence of the importance of PARP trapping is demonstrated by the greater cytotoxic effect of PARPis compared with PARP depletion (PARP1/2 -/-) in BRCAdeficient cells as well as the development of resistance to PARPi treatment by decreased PARP1 expression. 29 A third hypothesis combines both mechanisms, suggesting that catalytic inhibition of PARP1 via PARPis prevents automodification of the PARP1 enzyme, resulting in a stabilization of the PARP-DNA interaction. 30 Research regarding the precise mechanisms of PARPi action and their effect on tolerability will be an important part of their application to specific tumor types.
PARPis: Early Clinical Results
The hypothesis-driven development of PARPis led to the rapid initiation of clinical trials using single-agent PARPis to treat patients with BRCA-deficient tumors, namely breast and ovarian cancers. Single-agent use of AZD-2281 (olaparib) was recently approved by the US Food and Drug Administration (FDA) for the treatment of women with recurrent ovarian cancer carrying a germline BRCA mutation who were treated with 3 prior lines of chemotherapy. This approval was partly based on the results of a phase 2, international, multicenter, single-arm trial of 193 heavily pretreated (average, 4.3 lines of prior therapy) women with confirmed germline BRCA-mutated ovarian cancer. Patients were given 400 mg of olaparib twice daily until toxicity or disease progression. They reported an overall response rate of 31%, stable disease (at 8 weeks) in 40% of patients, and a median overall survival of 16.6 months. 31 Ledermann et al also conducted a phase 2, randomized, placebo-controlled study of maintenance treatment with olaparib in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had previously received 2 platinum-based regimens and had achieved a partial or complete response to their most recent regimen. BRCA1/2 carrier mutation status was not required. Patients were randomly assigned to receive 400 mg of olaparib twice daily or placebo within 8 weeks of the completion of their last dose of platinum-based chemotherapy until disease progression. Progression-free survival (PFS) was significantly longer in the patients treated with olaparib (median, 8.4 months vs 4.8 months; P<.001), although there was no difference in overall survival noted at the time of interim analysis (38% maturity) The lower risk of disease progression was present in all subgroups analyzed (although there were too few patients with wild-type BRCA1/2 for analysis). The toxicity profile was similar to that of previous reports and there were no significant differences noted between the groups with regard to health-related quality of life.
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Although single-agent PARPis have been effective in select patients, their tumoricidal effect may be enhanced when administered with DNA-damaging chemotherapy. Multiple preclinical studies have confirmed the ability of PARPis to potentiate DNA-damaging agents such as cisplatin and carboplatin in BRCA1 -/-or BRCA2 -/-cell culture and xenograft tumor models. [33] [34] [35] [36] Platinum-based agents, such as cisplatin or carboplatin, induce intrastrand (repaired via nucleotide excision repair) and interstrand DNA crosslinks (repaired partly via HR). 37 It is hypothesized that combinatorial therapy with PARPi and platinum-based agents, results in the increased accumulation of DSBs which cannot be repaired as efficiently in patients deficient in HR. 38 Patients with BRCA1/ 2-deficient breast and ovarian tumors appear to have an inherent sensitivity to platinum-containing chemotherapeutic regimens. This was demonstrated by improved PFS, overall survival, and higher partial and complete response rates compared with patients lacking these mutations. [39] [40] [41] [42] [43] [44] [45] PARPi combined with platinum-based chemotherapy may exploit this inherent sensitivity which is likely due to HR deficiency, and has been tested in a randomized, open-label, phase 2 study in patients with recurrent high-grade serous ovarian cancer who had received 3 previous courses of platinum-based chemotherapy with >6 months to disease progression after their last treatment. Germline BRCA mutation status for these patients was known, and patients were randomized to receive olaparib plus paclitaxel and carboplatin or paclitaxel and carboplatin without additional therapy. Although this cohort of patients was heavily pretreated, the PFS was significantly longer in the group treated with olaparib plus chemotherapy (median, 12.2 months [95% CI, 9. 46 A clinical trial (ClinicalTrial.gov identifier NCT02470585) to evaluate combination therapy (veliparib plus carboplatin plus paclitaxel vs carboplatin plus paclitaxel) in previously untreated patients with stage III or IV high-grade serous epithelial ovarian cancer is currently recruiting.
Although these results were promising, the relative low frequency of germline BRCA mutations in other solid tumors appeared to initially limit the clinical application of PARPi. Fortunately, advances in next-generation sequencing technology have enabled the analysis of the genetic complement of thousands of tumors. This led to the identification of novel somatic mutations in genes encoding for components involved in HR that can functionally mimic BRCA loss and synergize with PARPi treatment. This concept was termed "BRCAness," defined as a tumor with HR deficiency without a deficiency in BRCA1/2. The list of genes that, when mutated, may be involved in HR deficiency continues to expand (Table 2) . [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Mutations in genes associated with transcriptional regulation and cell cycle control that affect DNA repair also have been shown to confer sensitivity to PARPi (Table 2) . [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Clinical data to support this notion that PARPis have more broad antitumor activity has recently been reported with niraparib as maintenance treatment for women with platinum-sensitive, recurrent ovarian cancer. Although women with germline BRAC1/2 mutations and those with HR deficiency benefited the most from treatment with niraparib, women with neither of these predictive features still benefited compared with placebo (PFS of 9.3 months vs 3.9 months; P<.001). 66 These discoveries may potentially lead to an expanded application of PARPi in the treatment of tumors that are genetically wild-type for BRCA1/2 but deficient in HR due to somatic or germline mutations in other genes associated with HR-mediated DNA repair.
PARPi holds a great deal of promise in the management of GU cancers such as prostate and urothelial cancer. The genomes of PCa and UC have been shown to contain reasonable subsets of tumors with somatic mutations in genes implicated in the HR pathway in both early-stage and late-stage disease (Fig. 2) . [67] [68] [69] In this article, we summarize the scientific rational for targeting PARP1 in patients with GU cancers, previously reported preclinical and clinical trials, and ongoing trials attempting to determine how PARPis can best be used in the management of patients with GU cancers, particularly those with mutations in genes associated with HR. 71, 72 Unfortunately, the majority of patients with metastasis will progress to castration-resistant PCa (CRPC) despite androgen blockade within 2 to 3 years. 73 Although additional treatments exist for patients with metastatic CRPC, including docetaxel, enzalutamide, abiraterone, radium-223, sipuleucel-T, and cabazitaxel, these therapies are not effective in all men. Responses are not durable, and provide only a modest overall survival benefit. 74 The comprehensive genetic characterization of PCa identified a significant number of germline and somatic mutations in DNA repair genes, specifically those involved in HR. 75, 76 Given the frequency of these HR gene mutations (up to 17%-19% in patients with metastatic CRPC), 77 the paradigm of PARPi synthetic lethality likely will be an important addition to the management of patients with prostate cancer, particularly in the metastatic setting.
PARPI AND PROSTATE CANCER
Genetic Characterization of Prostate Cancer and DNA Damage Repair Deficiency
Prostate cancer is now firmly recognized as a cancer that is predisposed in men carrying germline BRCA mutations. The relative risk of developing prostate cancer for men with germline BRCA1 mutations who are aged <65 years is 1.8 (95% CI, 1.01-3.29) and is 8.6 in men with germline BRCA2 mutations (95% CI, 5.1-12.6). 78 BRCA mutation carriers are significantly more likely to present with a Gleason score of 8, T3/T4 disease, lymph node involvement, and metastasis compared with noncarriers. 79 Pritchard et al used whole-exome sequencing or targeted next-generation sequencing assays in a large population of men with biopsy-proven metastatic prostate cancer and found that 11.8% had at least 1 presumed pathogenic germline mutation in a gene involved in DNA repair, the majority of which were implicated in HR.
68 BRCA1/2 germline mutations were found in 6% of patients with metastatic disease, which is in contrast with <1% of men with localized prostate cancer. These provocative data suggest the enrichment of germline BRCA1/2 mutation carriers and other germline DNA repair mutation carriers in metastatic versus localized disease.
Somatic HR gene mutations including BRAC1/2 and ATM also appear to be present in a significant subset of patients with PCa. The Cancer Genome Atlas (TCGA) performed a comprehensive molecular characterization of localized prostate cancer specimens after radical prostatectomy and found that 9% of tumors had somatic mutations (truncating or missense) in genes associated with HR and the repair of DSBs (BRCA1/2, FANCD2, CKD12, and ATM). 80 The mutation frequency of these genes appears to be even greater in patients with more aggressive disease or disease of a later stage. Robinson et al identified alterations in DNA repair genes (BRCA1/2, ATM, CDK12, FANCA, and RAD51B/C) in 15% of 150 metastatic CRPC biopsy samples, with many of these gene products found to be associated with HR. 77 The existing germline and somatic genetic data suggest that DNA repair, specifically HR, may have metastasissuppressor properties indirectly and/or perhaps directly in prostate cancer. These data make a compelling argument that men with metastatic prostate cancer should consider undergoing both germline and somatic mutation HR gene testing.
Unique Features of PARP1 in Patients With Prostate Cancer
Molecular studies have suggested that PARP1 may play a functional role in prostate cancer progression. PARP1 directly regulates the androgen receptor (AR), and PARPi decreases recruitment of the AR to target promoters.
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PARP1 also may be involved in the regulation of AR activity at later stages of androgen-independent action. PARP1 activity is significantly increased in CRPC cells compared with hormone-sensitive prostate cancer cells, and PARPi causes depletion of both the AR and PARP1 on chromatin in CRPC cells. 81 Conversely, the AR itself also may be involved in the upregulation of DSB repair in PCa. 82, 83 These results indicate that PARPi may have a unique multimodal mechanism of action in the treatment of prostate cancer.
The most common gene fusions in PCa involve TMPRSS2-ERG, which is found in >50% of cases of metastatic PCa. 69, 77, 80 ERG is an oncogene of the ETS family of transcription factors and TMPRSS2 is an androgenregulated gene preferentially expressed in the prostate. The TMPRSS2-ERG fusion can result in androgen-regulated overexpression of ERG. To the best of our knowledge, the clinical significance of the TMPRSS2-ERG fusion is unknown, but its presence is associated with PARPi sensitivity in vitro and in vivo. 84 The mechanistic rationale was described by Brenner et al, 84 who demonstrated that ERG interacts with PARP1 via DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) and that PARP1 is required for ERG-mediated transcription. Overexpression of ERG increases the accumulation of DSBs and treatment with ERG small interfering RNA was found to lead to a reduction in detectable DSBs. Treatment of ETS-positive tumors with olaparib led to significantly diminished growth in xenograft models compared with ETS-negative tumors. 84 Somatic loss of function mutations in the tumor suppressor phosphatase and tensin homolog (PTEN) (found in 15% and 40%, respectively, of localized and metastatic prostate tumors) results in impaired HR capacity and confers PARPi sensitivity similar to BRCA1/2 deficiency in prostate cancer cells. 77, 80, 85, 86 Although clinical evidence to date has not demonstrated an association between these features and response to PARPi, these unique interactions may provide the basis for other possible therapeutic implications for PARPi in prostate cancer in combination with androgen deprivation therapy, chemotherapy, and/or radiotherapy.
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PARP1 Inhibition Clinical Trials in Patients With Prostate Cancer
To the best of our knowledge, one of the first studies to demonstrate a clinical benefit of PARPi in PCa was a phase 1 trial of olaparib in 60 patients with solid tumors who were germline BRCA mutation carriers. 88 Of the 3 patients with CRPC, 1 patient was a BRCA2 mutation carrier and had resolution of their bony metastasis and a >50% decrease in their prostate-specific antigen (PSA). 88 These preliminary results enabled further trials in patients with advanced PCa. Hussain et al performed a single-arm pilot study to determine the safety and efficacy of temozolomide (TMZ) combined with veliparib in patients with metastatic CRPC who had developed disease progression after treatment with docetaxel. 89 TMZ is an alkylating agent that generates DNA adducts, which can produce SSBs during the process of their repair. PARP1 can bind to these SSBs, and in the presence of PARPis facilitate PARP1 trapping. 90 For these reasons, TMZ has shown success in combination with PARPi in other tumor types. 91 Veliparib increased the sensitivity of prostate cancer cells to TMZ in vitro and in vivo. 34, 92 Veliparib also reversed resistance to TMZ in a mouse model of prostate cancer, resulting in improved overall survival. 92 Of the 25 patients evaluated in this study, 2 achieved a partial response (8%), 13 (52%) had a stable PSA, and 10 patients (40%) experienced disease progression. Patients were not prescreened for somatic or germline HR-mediated DNA repair gene mutations, although 8 of the 25 patients were assessed for TMPRSS2-ERG fusion (which was found to be present in only 1 patient). The combination was tolerable, but demonstrated limited clinical activity. 87 The lack of prescreening for HR deficiency status, the low dose of veliparib, the weak ability of veliparib to trap PARP1, and the unproven benefit of TMZ in patients with metastatic CRPC likely contributed to these modest results.
The Trial of PARP Inhibition in Prostate Cancer (TOPARP-A) sought to determine whether patients with metastatic CRPC responded to treatment with full-dose olaparib. 50 TOPARP-A was a phase 2 study in which 49 patients with metastatic CRPC were treated with olaparib at a dose of 400 mg twice daily. Prior therapies included docetaxel (49 men; 98%), abiraterone or enzalutamide (49 men; 98%), and cabazitaxel (29 men; 58%). Before treatment, men underwent biopsy, and their tumors were sequenced with exome and transcriptome analysis. In 16 of the 49 patients (33%), homozygous deleterious mutations were found in HR repair genes (BRCA1/2, ATM, CHEK2, and FANCA). Of these patients, 88% demonstrated a response to olaparib. Only 2 of the 33 (6%) patients who were negative for HR deficiency (HRD) achieved a clinical response. The median overall survival was 13.8 months in the HRD group versus 7.5 months in the HR wild-type group (P 5 .05). Dose reductions to 300 mg twice daily were required in 13 patients, and anemia was the most common cause of dose reduction (7 patients). These results highlight the potential application of a biomarker (ie, HRD) for the preselection of men who may benefit from PARPis. This study resulted in the FDA granting olaparib breakthrough therapy designation for patients with BRCA1/2 or ATM-mutated metastatic CRPC who had received a prior taxane-based chemotherapy and at least 1 next-generation, AR-directed therapy (enzalutamide or abiraterone).
NCI9012 was a phase 2 study of patients with metastatic CRPC in which metastatic tumors were biopsied and assessed for ETS fusions (ie, TMPRSS2-ERG), stratified by their ETS fusion status, and patients then were randomized to receive abiraterone or abiraterone plus veliparib. The primary endpoint was PSA response. Secondary endpoints included safety, objective response rate, and PFS. In that study, 185 eligible patients underwent biopsy (89 of soft tissue and 96 of bone); 159 (86%) had adequate tissue and 35% were found to be positive for ETS. Exploratory analysis from sequencing biopsy tissue (75 patients) was performed, in which 19 patients (25%) had a DNA repair gene deficiency (DRD; homozygous deletions or deleterious mutations of BRCA1, BRCA2, ATM, FANCA, PALB2, RAD51B, and RAD51C). Preliminary results revealed a trend in favor of the combination of abiraterone plus veliparib for PSA response (71% vs 64%; P 5 .33), objective response rate (53% vs 43%; P 5 .32), and median PFS (11 months vs 8.8 months; P 5 .87). 87 Regardless of treatment, patients with somatic deleterious DRD mutations were found to have a longer median PFS (13.5 months [95% CI, 8.2 months-not reached] vs 5.8 months [95% CI, 4.2-8.2 months]; P 5 .01) and a higher PSA response rate (89% vs 57%; P 5 .02) compared with those without somatic DRD mutations. These data suggest that patients with DRD mutations may have an improved response to either PARPi or androgen deprivation therapy, through unexplained mechanisms. The increase in the frequency of DRD mutations found in CRPC compared with early confined cancers suggests that these tumors may undergo selection during disease progression. Future studies that attempt to identify the mechanism of interaction between DRD mutations, AR signaling, and PARP inhibition will be important to optimize treatment. A summary of ongoing clinical trials with PARPis for the treatment of patients with PCa is listed in Table 3 .
PARPI AND BLADDER UC
Greater than 77,000 new cases of UC will be diagnosed in 2016 in the United States, representing 4.6% of all new cancer cases. 70 Approximately 30% of newly diagnosed patients present with muscle-invasive bladder cancer, 50% of whom will progress to distant metastasis, and 5% will initially present with metastatic disease. 93 Unfortunately, neither the management nor the mortality of UC has changed significantly in >30 years. UC is responsive to systemic chemotherapy of multidrug platinum combinations. The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) was first applied to patients with UC in 1985, 94 and still is used today with a slight modification of the dose and schedule (dose-dense MVAC). Before 2016, the only change in systemic therapy for patients with UC was the combination of gemcitabine and cisplatin that became an alternative to MVAC in the 2000s after it demonstrated similar outcomes with less toxicity. 95 For >25 years, no new agents were approved by the FDA. The programmed death-ligand 1 inhibitors atezolizumab and nivolumab were approved by the FDA in 2016 and granted breakthrough status as second-line immunotherapy for patients with locally advanced or metastatic disease that has progressed during or after platinumcontaining chemotherapy. These decisions were based on studies revealing similar, sufficient safety and efficacy (median PFS of 2.1 months for atezolizumab [95% CI, 2. 96, 97 Unfortunately, only 20% to 30% of patients with metastatic UC will achieve a partial or complete response to checkpoint immunotherapy, and to the best of our knowledge there currently are no reliable methods with which to predict response. 96 Thus, further research to identify new strategies for the treatment of UC remain a critical focus.
Genetic Characterization of Bladder Cancer and DNA Damage Repair Deficiency
The characterization of the genomic landscape of UC has identified targetable genomic alterations, including a high number of loss of function mutations in DNA damage repair genes. 39, 83, 84 In 2004, Bentley et al 98 hypothesized that a deficiency in the repair of DSBs may be responsible for the high frequency of chromosomal instability observed in patients with bladder cancer. Before the identification and isolation of specific proteins involved in DNA damage repair, crude nuclear extracts from high-grade bladder carcinoma were found to be more error-prone compared with extracts from normal urothelial cells for in vitro DNA repair. 98 The TCGA analysis of bladder UC provided a possible explanation for these results because truncating and missense mutations in genes associated with the BRCAness phenotype and genes known to confer PARPi sensitivity (CHEK1/2, RAD51, BRCA1/2, ATM, ATR, MDC1, and FANCF) were identified in 34% of tumors (TCGA, Bladder Urothelial Carcinoma provisional, 2015). 67, [99] [100] [101] [102] Similar to BRCA-deficient breast and ovarian cancers, sensitivity to neoadjuvant platinum-based chemotherapy is significantly associated with mutations in genes involved in HR repair.
Plimack et al 103 found that response to neoadjuvant cisplatin chemotherapy was associated with mutations in general DNA repair genes (P<.001), some of which are strongly associated with HR (ATM and FANCC). Of the patients who responded, 13 of 15 (87%) were found to have deleterious mutations in genes associated with DNA repair, whereas none of the nonresponders contained these mutations. The presence of these mutations also was found to be associated with significantly improved PFS (P 5.0085) and overall survival (P 5.007). The rate of pT0 or complete response was 41% in DRD-positive patients. 103 The prevalence of these somatic mutations in HR genes as well as their association with platinum sensitivity suggests PARP to be a rational target for the treatment of UC in select patients.
PARP1 Inhibition in Bladder Cancer
To the best of our knowledge, the only published data regarding PARPi in patients with UC is in preclinical cell culture and xenograft models. Jian et al 104 evaluated the effect of the PARPi CEP-9722 and its active metabolite CEP-8983 in human UC cell lines and xenograft models of nude mice. Cells and xenografts were treated with cisplatin, CEP-8983 alone, or a combination of cisplatin and CEP-8983. Western blot analysis and immunofluorescence were used to assess DNA repair proteins (ATM, BRCA1, meiotic recombination 11
[MRE11], RAD51, RAD50, CHK1, and CHK2) and to quantify HR-mediated DNA DSB repair. Radiationinduced RAD51 nuclear localization was used as functional marker of HR repair activity. As the authors hypothesized, a reduced capacity for HR repair (decreased RAD51 nuclear localization) was associated with increased sensitivity to PARPi. The combination of PARPi and cisplatin caused a significant increase in DNA damage versus use of cisplatin alone. 104 Although these preclinical results are encouraging, to the best of our knowledge there are no clinical trials to date of PARPi in patients with bladder UC. 
FUTURE DIRECTIONS
Continuing larger trials with PARPis in patients with PCa will be essential to validate their clinical benefit. Expanding preclinical in vitro and in vivo models in UC to validate the efficacy of PARPi monotherapy as well as combination therapy is the first step toward clinical trials in selected patients with metastatic UC and HR deficiency. Given the early preliminary data, the development of accurate, timely, and cost-efficient methods of predicting response to PARPi is desperately needed. Although several genes involved in DNA repair, and more specifically HR, have been identified to confer sensitivity to PARPi, limiting PARPi use to this small cohort of HR genes could significantly limit the patient population who may benefit from these medications. Multiple approaches currently are underway to develop biomarkers for the identification of patients who will respond to PARPi. For example, Larsen et al analyzed 55 familial BRCA1 or BRCA2 breast tumors and 128 sporadic breast tumors to identify a transcriptional signature of DNA repair deficiency. 105 Others have been working to develop functional HR assays via immunostaining using surrogates such as RAD51 or MRE11 localization. 106, 107 One assay that combines tumor sequencing with DNA cytogenetics is the Myriad HRD test (Myriad Genetics, Salt Lake City, Utah). The Myriad HRD test is performed on formalin-fixed, paraffin-embedded tumor samples evaluating for 54,091 single-nucleotide polymorphisms as well as 43 genes involved in HR, including BRCA1 and BRCA2. An HRD score is calculated based on loss of heterozygosity, largescale transitions, and telomeric allelic imbalance. The Myriad HRD test has been validated in patients with breast cancer, 108 and recently in those with ovarian cancer. Using the Myriad HRD test, Timms et al analyzed samples from the NOVA study, a phase 3 trial of niraparib in patients with platinum-sensitive ovarian cancer who either had a germline BRCA1/2 mutation or responded to their most recent platinum-based chemotherapeutic regimen. All patients in the germline BRCA1/ 2 mutation cohort met the cutoff score for HRD, as did 55% of patients in the nongermline BRCA1/2-mutated cohort. 109 Patients who met the cutoff score in the nongermline BRCA1/2-mutated cohort also had a significant improvement in PFS compared with placebo (median, 12.9 months vs 3.8 months; P<.0001). 109 A positive HRD score, or meeting the cutoff for HRD, also has been shown to predict pathologic response to neoadjuvant chemotherapy in patients with triple-negative and BRCA1/2-mutated breast cancer. 110 Preclinical studies currently are underway to validate the accuracy of these tools to predict HRD and PARPi sensitivity in patients with PCa and bladder UC. For example, we currently are obtaining whole-genome sequencing and HRD scores of xenografts derived from patients with bladder UC. These models are then exposed to placebo, PARPi alone, cisplatin alone, or PARPi plus cisplatin to determine whether the HRD score can predict response (change in size of tumor).
After establishment of PARPi efficacy in GU cancers and the identification of predictive biomarkers for selecting PARPi candidates, our next challenge will be to determine how to apply PARPis in patients with GU cancers to achieve the maximum benefit. Ultimately, patients may not only benefit in the metastatic or adjuvant setting but also from the neoadjuvant application of PARPi. For example, patients who are ineligible for cisplatin may benefit from the neoadjuvant use of PARPi combined with carboplatin chemotherapy. 111 Adjuvant use of PARPi in patients with high-risk or micrometastatic PCa could potentially render them disease free or be combined with androgen deprivation in patients with lymph node-positive disease. Developing trials to answer these questions could progress rapidly with the application of new biomarkers and next-generation sequencing.
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